PharmEng LogoPharmEng Banner
Latest News  

PharmEng
announces Closing of Private Placement
MORE

PharmEng
Board Changes
MORE

PharmEng
CFO Change Announcement
MORE

PharmEng
reports second quarter earnings for 2008
MORE

PharmEng
receives site license from Health Canada to manufacture natural health products for the facility in Sydney, Nova Scotia
MORE

PharmEng
receives Establishment License from Health Canada for new facility in Sydney, Nova Scotia
MORE

PharmEng
relocates Perth, Ontario pharmaceutical contract manufacturing operations to new facility in Sydney, Nova Scotia
MORE

PharmEng
reports first quarter earnings for 2008
MORE

PharmEng
reports earnings for 2007
MORE

PharmEng
names John Durham as Corporate Vice President, Business Development, Keata Pharma Inc.
MORE

PharmEng
names John Carkner as President, Keata Pharma – Arnprior, Ontario facility
MORE

PharmEng
completes acquisition of Pfizer manufacturing facility, announces closing of $20 million debt financing and full payout of amounts owing to Shropshire S.a.r.L.
MORE

PharmEng
announces purchase of Pfizer manufacturing facility in Arnprior, ONT.
MORE

PharmEng
reports third quarter earnings for 2007
MORE

PharmEng
announces opening of pharmaceutical manufacturing facility in Cape Breton, N.S.
MORE

PharmEng
International Inc. announces full payout of Laurus obligation
MORE

Shropshire S.ΐ R.L exercises warrants of PharmEng International inc.
MORE

PharmEng
names David G. Leonard as President Keata Pharma
MORE

PharmEng
announces completion of final tranche of private placement
MORE

PharmEng
International Inc. closes China acquisition
MORE

PharmEng
reports earnings for 2006
MORE

PharmEng
International Inc. completes additional $3 M private placement financing
MORE

PharmEng
International Inc. closes private placement financing
MORE

PharmEng
announces exclusive agreement with Chinese manufacturer for distribution of acetaminophen to North America resulting in significant raw material cost savings
MORE

PharmEng
announces opening of San Francisco offices with $1.6 M (US) in 2006 contracts and completion of the biopharmaceutical certificate program in Taiwan
MORE

PharmEng
issues securities in connection with private placements
MORE

PharmEng reports third quarter earnings for 2006
MORE

PharmEng
names Bert Loveless As Chief Financial Officer
Bernie Boudreau elected To The Board
MORE

PharmEng reports Second Quarter Earnings for 2006
MORE

PharmEng announces Board Changes
MORE

PharmEng International Inc. completes Financings
MORE

PharmEng starts Training Program in Taiwan in Collaboration With The University of Waterloo and The National Research Institute.
MORE

PharmEng extends Vertical Intergration Strategy and Acquires Laboratory Instru-mentation Solution Services Company
MORE

PharmEng International Inc. announces Extension Of Warrant Term For 2004 Warrants
MORE

PharmEng names Lawrence Tjan as Chief Financial Officer
MORE

PharmEng reports earnings for 2005
MORE

Euro-Pharm selects PharmEng as private label supplier
MORE

PharmEng signs Letter of Intent to purchase Beijing pharmaceutical consulting company
MORE

Pirri selects PharmEng as exclusive supplier
MORE

Tanta selects PharmEng as strategic supplier
MORE

MEDEC PULSE magazine posted our new manufacturing facility in Nova Scotia
MORE

PharmEng offices, announces opening of Halifax office
MORE

PharmEng named to TSX Venture 50
MORE

Pictures of Sod Turning Ceremony in Cape Breton, N.S.
MORE

Sod Turning Ceremony marks start of construction of first pharmaceutical manufacturing facility in Cape Breton, N.S.
MORE

PharmEng opens offices, announces $1.7M U.S. contract in Raleigh, North Carolina
MORE

2005 NHP Vancouver Training.
MORE

PharmEng announces manufacturing contracts.
MORE

PharmEng reports second quarter earnings for 2005.
MORE

PharmEng closes final tranche of private placement.
MORE

PharmEng adds to Senior Management Team.
MORE

PharmEng releases strong 2004 results.
MORE

PharmEng acquires platform for new manufacturing capacity.
MORE

Chrysalis Capital Corporation closes business combination with PharmEng. MORE

PharmEng Receives Best International Business Award. MORE

NEWS ARCHIVE

Biosciences Eastern & Central Africa Environmental Assessment Project
PharmEng

PharmEng is a full-service consulting and contract manufacturing company that serves the pharmaceutical, biotechnology and medical device industries in North America and internationally.

 

Consulting services include:

• Validation
• Engineering
• Product Development
• Lab Instrumentation
• Quality Systems
• Professional Training
• Medical Devices
• Regulatory Affairs

Contract manufacturing services include pharmaceutical support, formulation development, laboratory testing, and the manufacturing of finished solid dosage and liquid products.

PharmEng ’s primary consulting focus is to work in close collaboration with clients to provide innovative and cost-effective solutions to help maintain their competitive advantage. Along with a focus on service quality, PharmEng has emerged as a worldwide leader in pharmaceutical consulting. The Company’s success is demonstrated by the numerous long-term relationships PharmEng has developed in the pharmaceutical, biotechnology, nutraceutical, healthcare, and API (active pharmaceutical ingredients) sectors

Our winning formula of working in collaboration with our clients is demonstrated by the long-term relationships we have developed in the industry.

"Our goal is to provide innovative and cost-effective engineering, validation, regulatory affairs and regulatory compliance solutions for our clients to successfully maintain their competitive advantage."

Alan Kwong
CEO and Managing Director

 

  VIEW OUR

 Current Course Schedule
 Certification Programs

  • Cape Breton University

  • University of Waterloo & the
    National Health Research
    Institutes (NHRI)
 
Want to be a part of our excellent team? Click here for career opportunities.
 

Toronto (CA) Vancouver (CA)
Winnipeg (CA) Montreal (CA)
Sydney (CA) Raleigh (US)
Beijing (CN) Taipei (TW)

 
 
PharmEng Technology Inc. All Rights Reserved.